Peptide inhibition of neointimal hyperplasia in vein grafts

David Calcagno, John Conte, Marcus H. Howell, Marie L. Foegh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Angiopeptin, a novel synthetic octapeptide, was evaluated as a new approach toward the inhibition of neointimal hyperplasia in vein grafts. Male New Zealand white rabbits (n = 22) underwent carotid artery interposition bypass grafting with autologous reversed jugular vein. Nine rabbits were in the treatment group, and 13 were in the control group. The treatment group received angiopeptin 20 μg/kg/day by subcutaneous injection beginning 1 day before operation and continuing for 3 weeks until they were killed. At death the vein grafts were fixed in situ with 10% buffered formalyn at 80mm Hg perfusion pressure. Histologic sections through each vein graft were analyzed by computerized morphometric analysis for area of neointimal hyperplasia (mm2). Neointimal hyperplasia in the control animals was 0.080 + 0.017 mm2 (mean + SEM), whereas neointimal hyperplasia in the group treated with angiopeptin was 0.022 + 0.006 mm2 (mean + SEM) (p = 0.02). This is the first time that peptide inhibition of neointimal hyperplasia has been demonstrated in vein grafts and may have significant implications for future use in vascular surgery.

Original languageEnglish (US)
Pages (from-to)475-479
Number of pages5
JournalJournal of Vascular Surgery
Volume13
Issue number4
DOIs
StatePublished - Jan 1 1991

Fingerprint

Hyperplasia
Veins
Transplants
Peptides
Rabbits
Jugular Veins
Subcutaneous Injections
Carotid Arteries
Blood Vessels
Perfusion
Pressure
Control Groups
Therapeutics
angiopeptin

All Science Journal Classification (ASJC) codes

  • Surgery
  • Cardiology and Cardiovascular Medicine

Cite this

Calcagno, David ; Conte, John ; Howell, Marcus H. ; Foegh, Marie L. / Peptide inhibition of neointimal hyperplasia in vein grafts. In: Journal of Vascular Surgery. 1991 ; Vol. 13, No. 4. pp. 475-479.
@article{8ae801b4dd8146abab73154df1e401a6,
title = "Peptide inhibition of neointimal hyperplasia in vein grafts",
abstract = "Angiopeptin, a novel synthetic octapeptide, was evaluated as a new approach toward the inhibition of neointimal hyperplasia in vein grafts. Male New Zealand white rabbits (n = 22) underwent carotid artery interposition bypass grafting with autologous reversed jugular vein. Nine rabbits were in the treatment group, and 13 were in the control group. The treatment group received angiopeptin 20 μg/kg/day by subcutaneous injection beginning 1 day before operation and continuing for 3 weeks until they were killed. At death the vein grafts were fixed in situ with 10{\%} buffered formalyn at 80mm Hg perfusion pressure. Histologic sections through each vein graft were analyzed by computerized morphometric analysis for area of neointimal hyperplasia (mm2). Neointimal hyperplasia in the control animals was 0.080 + 0.017 mm2 (mean + SEM), whereas neointimal hyperplasia in the group treated with angiopeptin was 0.022 + 0.006 mm2 (mean + SEM) (p = 0.02). This is the first time that peptide inhibition of neointimal hyperplasia has been demonstrated in vein grafts and may have significant implications for future use in vascular surgery.",
author = "David Calcagno and John Conte and Howell, {Marcus H.} and Foegh, {Marie L.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1016/0741-5214(91)90300-J",
language = "English (US)",
volume = "13",
pages = "475--479",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "4",

}

Peptide inhibition of neointimal hyperplasia in vein grafts. / Calcagno, David; Conte, John; Howell, Marcus H.; Foegh, Marie L.

In: Journal of Vascular Surgery, Vol. 13, No. 4, 01.01.1991, p. 475-479.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Peptide inhibition of neointimal hyperplasia in vein grafts

AU - Calcagno, David

AU - Conte, John

AU - Howell, Marcus H.

AU - Foegh, Marie L.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Angiopeptin, a novel synthetic octapeptide, was evaluated as a new approach toward the inhibition of neointimal hyperplasia in vein grafts. Male New Zealand white rabbits (n = 22) underwent carotid artery interposition bypass grafting with autologous reversed jugular vein. Nine rabbits were in the treatment group, and 13 were in the control group. The treatment group received angiopeptin 20 μg/kg/day by subcutaneous injection beginning 1 day before operation and continuing for 3 weeks until they were killed. At death the vein grafts were fixed in situ with 10% buffered formalyn at 80mm Hg perfusion pressure. Histologic sections through each vein graft were analyzed by computerized morphometric analysis for area of neointimal hyperplasia (mm2). Neointimal hyperplasia in the control animals was 0.080 + 0.017 mm2 (mean + SEM), whereas neointimal hyperplasia in the group treated with angiopeptin was 0.022 + 0.006 mm2 (mean + SEM) (p = 0.02). This is the first time that peptide inhibition of neointimal hyperplasia has been demonstrated in vein grafts and may have significant implications for future use in vascular surgery.

AB - Angiopeptin, a novel synthetic octapeptide, was evaluated as a new approach toward the inhibition of neointimal hyperplasia in vein grafts. Male New Zealand white rabbits (n = 22) underwent carotid artery interposition bypass grafting with autologous reversed jugular vein. Nine rabbits were in the treatment group, and 13 were in the control group. The treatment group received angiopeptin 20 μg/kg/day by subcutaneous injection beginning 1 day before operation and continuing for 3 weeks until they were killed. At death the vein grafts were fixed in situ with 10% buffered formalyn at 80mm Hg perfusion pressure. Histologic sections through each vein graft were analyzed by computerized morphometric analysis for area of neointimal hyperplasia (mm2). Neointimal hyperplasia in the control animals was 0.080 + 0.017 mm2 (mean + SEM), whereas neointimal hyperplasia in the group treated with angiopeptin was 0.022 + 0.006 mm2 (mean + SEM) (p = 0.02). This is the first time that peptide inhibition of neointimal hyperplasia has been demonstrated in vein grafts and may have significant implications for future use in vascular surgery.

UR - http://www.scopus.com/inward/record.url?scp=0025875379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025875379&partnerID=8YFLogxK

U2 - 10.1016/0741-5214(91)90300-J

DO - 10.1016/0741-5214(91)90300-J

M3 - Article

VL - 13

SP - 475

EP - 479

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 4

ER -